louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05584124: rTMS for Post-stroke Fatigue
Official title: Neuromodulation for Rehabilitation of Post-Stroke Fatigue: An rTMS Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke
Stroke, Chronic
Fatigue
Keywords: non-invasive brain stimulation
post-stroke fatigue
perception of fatigue
repetitive transcranial magnetic stimulation
rTMS
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
Collaborators: name: Ralph H. Johnson VA Medical Center
First posted: 2022-10-18
Enrollment: 60
Sex: ALL
Minimum age (years): 35
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This experimental trial is investigating the use of magnetic stimulation of the brain as a possible treatment for people with post-stroke fatigue. Fatigue is a common condition after a stroke and can negatively impact an individual's ability to perform desired social and physical activities. Magnetic stimulation of the brain has been shown to improve signs and symptoms of related psychological (e.g., depression) conditions. Participants in this trial will receive a type of magnetic stimulation called repetitive magnetic stimulation, or rTMS. The investigators will measure feelings of fatigue, and other clinical characteristics related to mood and cognition, before and after participants receive rTMS.


Eligibility criteria: Inclusion Criteria:

* 35 - 80 years of age
* more than 6 months post-stroke
* able to walk 10m unassisted
* Clinically present fatigue

Exclusion Criteria:

* Contraindications to MRI/TMS/rTMS (e.g. implanted metal within the head, history of seizures)
* Inability to follow simple three-step instructions
* Multiple strokes on opposite hemispheres
* Cerebellar and/or brainstem strokes
* Diagnosed comorbid neurological conditions (e.g. multiple sclerosis, Parkinson's disease, moderate/severe TBI)
* Comorbid psychological conditions (e.g. depression, anxiety, PTSD)
* strokes within stimulation sites
* Pregnancy
* Severe hypertension (resting SBP \> 200, DBP \> 120)

Primary outcomes:
measure: Change in Fatigue Severity Scale (FSS) score
timeFrame: Change from baseline FSS score to 7 days after last treatment
Secondary outcomes:
measure: Change in Modified Fatigue Impact Scale (MFIS) score
timeFrame: Change from baseline MFIS score to 7 Days after last treatment
measure: Change in Fatigue Severity Scale (FSS) score
timeFrame: Change from baseline FSS score to 3 months after last treatment
measure: Change in Modified Fatigue Impact Scale (MFIS) score
timeFrame: Change from baseline MFIS score to 3 months after last treatment
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Ralph H. Johnson VA Medical Center, Charleston, SC
state: South Carolina
Study officials:
affiliation: Ralph H. Johnson VA Medical Center, Charleston, SC
name: John H Kindred
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01974024: Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation
Official title: Antiemetic Corticosteroid Rotation From Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated With Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dexamethasone-induced Hiccup in Chemotherapy
Keywords: Dexamethasone
Hiccup
Chemotherapy
Methylprednisolone
Lead sponsor: Chung-Ang University
Sponsor class: OTHER
Collaborators: name: Gyeongsang National University Hospital
name: Dong-A University Hospital
name: Samsung Medical Center
First posted: 2013-11-01
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aims of this study were to investigate the feasibility of methylprednisolone rotation as treatment of DIH.

Detailed description: we planned a randomized prospective trial for cancer patients with DIH. The objective of the present study was to determine whether the rotation of corticosteroids affects the incidence and intensity of DIH without compromising the antiemetic efficacy.

Eligibility criteria: Inclusion Criteria:

* all solid cancer patients on chemotherapy
* age \>18 years
* received dexamethasone as an antiemetic

Exclusion Criteria:

* brain metastases
* hiccups before dexamethasone administration
* uncontrolled diabetes mellitus
* uncontrolled esophagitis or peptic ulcer

Primary outcomes:
measure: The intensities of hiccups
timeFrame: 2 months
Secondary outcomes:
measure: The intensities of emesis
timeFrame: 2 months
Other outcomes:
Locations:
city: Chiram-dong, Jinju-si
country: Korea, Republic of
facility: Gyeongsang National University Hospital
state: Gyeongsangnam-do
city: Dongjak-gu
country: Korea, Republic of
facility: Chungang University Hospital
state: Seoul
Study officials:
affiliation: Gyeongsang National University Hospital
name: Jung Hun Kang, M.D.
role: STUDY_CHAIR
References:
citation: Go SI, Koo DH, Kim ST, Song HN, Kim RB, Jang JS, Oh SY, Lee KH, Lee SI, Kim SG, Park LC, Lee SC, Park BB, Ji JH, Yi SY, Lee YG, Yun J, Bruera E, Hwang IG, Kang JH. Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Oncologist. 2017 Nov;22(11):1354-1361. doi: 10.1634/theoncologist.2017-0129. Epub 2017 Jul 7.
Clinical trial NCT01613924: Efficacy of Handheld Acne Heat Device
Official title: Efficacy of a Handheld Heat Based Device for the Spot Treatment of Mild to Moderate Acne Vulgaris: A Controlled Study to Determine Time to Resolution of Individual Inflammatory Lesions Using an Over-the-counter Acne Heat Device.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Acne Vulgaris
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2012-06-07
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Maximum age (years): 64
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of our study is to determine the time to resolution of individual acne lesions using a popular handheld heat based device in comparison to no treatment and to standard topical therapy with benzoyl peroxide in order to determine its effectiveness in the spot treatment of acne vulgaris. Patient satisfaction and potential side effects will be examined as well.


Eligibility criteria: Inclusion Criteria:

* Are 12- 64 years old
* Have an Investigator's Global Assessment of greater than or equal to 2
* Have 8-16 inflammatory acne facial lesions (papules and pustules)

Exclusion Criteria:

* Have any severe facial acne at baseline, including large acne lesions and cysts (nodulocystic acne)
* Have used any topical anti-acne medications, systemic antibiotics, and/or systemic corticosteroids 4 weeks before the study start
* Have used oral acne medications, such as Accutane (systemic retinoid), 6 months before the study start
* Have had a facial procedure 2 weeks before the study start
* Are nursing or pregnant
* Are using any oral contraceptives that have a specific anti-androgenic action or if you have started using a new oral contraceptive 12 weeks before the study start
* Are using any medications known to exacerbate acne
* Have a known hypersensitivity or allergy to benzoyl peroxide or any of the vehicle constituents
* Have a beard or facial hair that could interfere with study evaluations

Primary outcomes:
measure: Time to resolution of individual acne lesions
timeFrame: 5 days
Secondary outcomes:
measure: Device tolerability
timeFrame: 5 days
measure: Split-face investigator's static global assessment
timeFrame: 5 days
measure: Acne lesion counts
timeFrame: 5 days
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Skin Care Centre
state: British Columbia
Study officials:
affiliation: UBC Department of Dermatology and Skin Science
name: Shannon Humphrey, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05866224: Telerehabilitation Program and Detraining in Patients With Post-COVID-19 Sequelae
Official title: Effects of a Telerehabilitation Program and Detraining on Cardiorespiratory Fitness in Patients With Post-COVID-19 Sequelae
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19 Acute Respiratory Distress Syndrome
Lead sponsor: Campus docent Sant Joan de Déu-Universitat de Barcelona
Sponsor class: OTHER
First posted: 2023-05-19
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The primary objective of this study is to evaluate the effects of a 15-week home telerehabilitation program and a detraining period on cardiorespiratory fitness and muscular efficiency in patients with post-COVID-19 sequelae compared to a control group of COVID-19 patients. We hypothesize that cardiorespiratory fitness and muscular efficiency significantly improve in patients who carry out the home telerehabilitation program. However, the cardiorespiratory and muscular adaptations achieved and tolerance to exercise are lost over time as an effect of detraining.


Eligibility criteria: Inclusion Criteria:

* age \> 18 years
* molecular diagnosis (reverse transcription polymerase chain reaction \[RT-PCR\]) of infection by SARS-CoV-2
* post-COVID-19 symptomatology

Exclusion Criteria:

* severe neurological disease
* active oncological disease
* neuromuscular disease and/or orthopedic disorders impeding normal development of cardiopulmonary exercise test
* the absence of signed informed consent

Primary outcomes:
measure: Cardiorespiratory fitness: absolute oxygen uptake
timeFrame: 1 week per group
measure: Cardiorespiratory fitness: relative oxygen uptake
timeFrame: 1 week per group
measure: Exercise capacity during cardiopulmonary exercise test
timeFrame: 1 week per group
measure: Mechanical efficiency
timeFrame: 1 week per group
measure: Ventilatory efficiency
timeFrame: 1 week per group
measure: Power output during pedaling
timeFrame: 1 week per group
Secondary outcomes:
measure: Respiratory exchange ratio
timeFrame: 1 week per group
measure: Minute ventilation
timeFrame: 1 week per group
measure: ventilatory equivalent for oxygen
timeFrame: 1 week per group
measure: ventilatory equivalent for carbon dioxide
timeFrame: 1 week per group
measure: End-tidal partial pressure of oxygen
timeFrame: 1 week per group
measure: end-tidal partial pressure of carbon dioxide
timeFrame: 1 week per group
measure: Weight of COVID-19 patients
timeFrame: 1 week per group
measure: Height of COVID-19 patients
timeFrame: 1 week per group
measure: Body mass index of COVID-19 patients
timeFrame: 1 week per group
Other outcomes:
Locations:
city: Sant Boi De Llobregat
country: Spain
facility: Manuel Vicente Garnacho Castaño
state: Barcelona
Study officials:
References:
Clinical trial NCT02768324: the Effect of Gut Microbiota on the Prognosis of Sepsis
Official title: the Effect of Gut Microbiota on the Prognosis of Sepsis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sepsis
Keywords: sepsis
Gastrointestinal Microbiome
Gut microbiota
Gut Flora
Intestinal Flora
Lead sponsor: Jinan University Guangzhou
Sponsor class: OTHER
First posted: 2016-05-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with sepsis were included in this study

Brief summary: Sepsis is a life-threatening condition that arises when the body's response to infection injures its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion. Clinically, sepsis patients with diarrhea often result in a bad prognosis. Gut microbiota consists of a complex community of microorganisms that live in the digestive tracts of animals. The gut microbiota comprises the largest and most diverse reservoir of mutualistic microorganisms associated with animals. The aims of this study is to determin the effect of gut microbiota on the prognosis of Sepsis, by using 16s pyrosequencing, comparing the blood culture result.


Eligibility criteria: Inclusion Criteria:

* Subjects diagnosed with sepsis
* 18 years to 65 years of age

Exclusion Criteria:

* patients had complications such as acute cerebral infarction or acute myocardial infarction
* The use of antibiotics, pro-prebiotics within 3 months
* \<18 years or \>65 years
* History of intestinal surgery
* patients withdraw from this study

Primary outcomes:
measure: Discharged from ICU
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04652024: Effect of Anorectal Biofeedback on Encopresis in School Aged Girls After Sexual Assault
Official title: Effect of Anorectal Biofeedback on Encopresis in School Aged Girls After Sexual Assault
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fecal Incontinence
Lead sponsor: Badr University
Sponsor class: OTHER
First posted: 2020-12-03
Enrollment: 30
Sex: FEMALE
Minimum age (years): 5
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Females who have been sexually abused anally, have a disturbed anorectal motility. They have an increased resting pressure at the lower part of the anal canal. When their rectum is suddenly distended, they tend not to have an initially increased pressure in the anal canal, and the recto-anal inhibitory reflex is markedly decreased amplitude which is caused by reflex contraction of the pelvic floor during the relaxation of the internal anal sphincter.

Detailed description: The cause of fecal incontinence after sexual abuse is the improper functioning of anal sphincter muscles, as a result of their damage and/or neurological changes including the disturbance perception of sensory stimuli from the anal canal. Biofeedback therapy using visual and verbal feedback techniques has emerged as an useful option in managing fecal incontinence and levator ani syndrome. The goal of biofeedback training is to improve bowel function by restoring a normal pattern of defecation.

Eligibility criteria: Inclusion Criteria:

* absent anal reflex,
* skin trifles around the anus,
* funnel shaped anus
* medically stable and able to follow instructions

Exclusion Criteria:

* sexual transmitted disease
* any medical condition that affect the anus potentially such as Crohn's disease,
* severe chronic constipation,
* myotonic dystrophy

Primary outcomes:
measure: anorectal manometrey
timeFrame: pre and after 3 months of intervention, increase in the change in the mean of initial parameters of the anal and squeeze pressure indicate improvement while decreases in the mean of first sensation and maximum tolerable volume indicate improvement
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Hanaa
Study officials:
References:
Clinical trial NCT07010224: Elastofibroma Dorsi: Analysis of Risk Factors and Surgical Outcomes in a Single-Center Retrospective Study
Official title: Silent Lesion of the Subscapular Region: Analysis of Risk Factors and Postoperative Outcomes of Elastofibroma Dorsi in a Single-Center Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Elastofibroma Dorsi
Keywords: Elastofibroma Dorsi
Subscapular Mass
Chest Wall Tumor
Risk Factors
Thoracic Surgery
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2025-06-08
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consists of adult patients (aged 18 and older) who were diagnosed with elastofibroma dorsi and underwent surgical resection at a single tertiary care center between 2010 and 2025. All included patients had histopathologically confirmed diagnoses and at least one month of postoperative follow-up available in hospital records.

Brief summary: This study aims to retrospectively evaluate patients who underwent surgical treatment for elastofibroma dorsi, a rare benign tumor typically located in the subscapular region of the chest wall. The study will analyze demographic and clinical features, risk factors, diagnostic imaging methods, postoperative complications, and recurrence rates. By identifying potential predictors of complications and recurrence, the study hopes to contribute to the understanding and management of this silent and often incidental lesion.


Eligibility criteria: Inclusion Criteria:

* Patients who underwent surgical treatment for elastofibroma dorsi
* Histopathological confirmation of the diagnosis
* Minimum of 1-month postoperative follow-up available
* Age 18 years or older
* Accessible medical and imaging records in hospital archives
* Signed informed consent available in patient records (if applicable)

Exclusion Criteria:

* Patients diagnosed with elastofibroma dorsi but not treated surgically
* Cases without histopathological confirmation
* Incomplete or insufficient medical and radiological records
* Postoperative follow-up period less than 1 month
* Patients younger than 18 years
* Absence of documented informed consent (if applicable)

Primary outcomes:
measure: Completion of Retrospective Data Collection Form
timeFrame: Within 3 months after data collection begins
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Nishio J, Isayama T, Iwasaki H, Naito M. Elastofibroma dorsi: diagnostic and therapeutic algorithm. J Shoulder Elbow Surg. 2012 Jan;21(1):77-81. doi: 10.1016/j.jse.2011.01.043. Epub 2011 Apr 27.
Clinical trial NCT06144424: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Official title: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atopic Dermatitis
Lead sponsor: Escient Pharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2023-11-22
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis


Eligibility criteria: Inclusion Criteria:

* Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
* BSA of 3% to 20% and a vIGA-AD score of ≥3

Exclusion Criteria:

* Other active skin diseases associated with chronic pruritus
* Clinically infected atopic dermatitis that requires antibiotic therapy
* Use of specific treatments for atopic dermatitis

Primary outcomes:
measure: Safety and tolerability of EP262
timeFrame: Measured from Day 1 to End of Study or Early Termination (Up to 10 weeks)
Secondary outcomes:
measure: Effect of EP262 on skin histology
timeFrame: Measured from Day 1 to Week 6
measure: Effect of EP262 on skin gene expression
timeFrame: Measured from Day 1 to Week 6
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Allervie Clinical Research
state: Alabama
city: Miami Lakes
country: United States
facility: RM Medical Research, Inc.
state: Florida
city: Plainfield
country: United States
facility: Indiana Clinical Trials Center
state: Indiana
city: Rockville
country: United States
facility: Lawrence J. Green, MD LLC
state: Maryland
city: Troy
country: United States
facility: Revival Research Institute, LLC
state: Michigan
city: Boardman
country: United States
facility: Optima Research Boardman
state: Ohio
city: College Station
country: United States
facility: J&S Studies, Inc.
state: Texas
city: South Jordan
country: United States
facility: Jordan Valley Dermatology Center
state: Utah
city: Spokane
country: United States
facility: Dermatology Specialists of Spokane
state: Washington
city: Montréal
country: Canada
facility: Innovaderm Research Inc.
state: Quebec
Study officials:
References:
Clinical trial NCT05108948: Research of Factors Determining the Improvement of Quality of Life at One Year of Adult Patients Treated for Spinal Deformity (COFTASD)
Official title: Research of Factors Determining the Improvement of Quality of Life at One Year of Adult Patients Treated for Spinal Deformity : Observational Study (COFTASD)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Spinal Deformity
Lead sponsor: Elsan
Sponsor class: OTHER
Collaborators: name: European Clinical Trial Experts Network
First posted: 2021-11-05
Enrollment: 866
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient over 18 years-old with spinal deformity operated

Brief summary: The objective of this study is to find the predictive factors of improvement of the quality of life of operated patients from spinal deformity.


Eligibility criteria: Inclusion Criteria:

* Age over 18 years-old
* Diagnosis of Adult Spinal Deformity with any of the deformity characteristics following:

  * Scoliosis with a Cobb angle ≥ 20 °
  * Vertical sagittal axis (SVA) ≥ 5 cm
  * Pelvic tilt ≥25 °,
  * Thoracic kyphosis with a Cobb angle ≥ 60 °
* Eligible for surgery
* Having given their participation agreement
* Affiliate or beneficiary of a social security scheme

Exclusion Criteria:

* Age under 18 years-old
* Patient unlikely to comply with follow-up
* Patient with long-term complete paraplegia
* Patient unable to understand and answer questionnaires in due to language difficulties or cognitive impairment
* Pregnant or breastfeeding woman
* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision

Primary outcomes:
measure: Factors associated with improved oswestry disability score
timeFrame: 15 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bruges
country: France
facility: Clinique du dos
Study officials:
References: